VCAR33
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Acute
Conditions
Leukemia, Myeloid, Acute
Trial Timeline
Dec 11, 2023 → May 28, 2025
NCT ID
NCT05984199About VCAR33
VCAR33 is a phase 1/2 stage product being developed by Vor Biopharma for Leukemia, Myeloid, Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT05984199. Target conditions include Leukemia, Myeloid, Acute.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Acute were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05984199 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Leukemia, Myeloid, Acute